Last reviewed · How we verify
An Open, Single Arm, Single Center Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Combined With Anlotinib as Maintenance Therapy in Patients With Limited Stage Small Cell Lung Cancer Without Progression After First-line Radiotherapy and Chemotherapy
To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory
Details
| Lead sponsor | Jinming Yu |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | 2023-05-30 |
| Completion | 2026-02 |
Conditions
- Limited Stage Small Cell Lung Cancer
- Not Progressed After First-line Chemoradiotherapy
Interventions
- TQB2450 Injection + Anlotinib Hydrochloride Capsules
Primary outcomes
- Adverse event — Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)
Incidence and severity of adverse events - serious adverse event — Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)
Incidence and Severity of Serious Adverse Events
Countries
China